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Structured abstract 
 
Background 
Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis 
(IE). We describe the characteristics of patients according to the type of valve replacement 
(mechanical or biological), and examine whether the type of prosthesis was associated with 
in-hospital and 1-year mortality. 
Methods and Results 
Among 5,591 patients included in the International Collaboration on Endocarditis Prospective 
Cohort Study, 1,467 patients with definite IE were operated on during the active phase and 
had a biological (37%) or mechanical (63%) valve replacement. 
Patients who received bioprostheses were older (62 vs 54 years), more often had a history of 
cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of 
health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more 
frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis 
group, 20.5% vs 14.0% (p=0.0009) and 25.3% vs 16.6% (p<.0001), respectively. 
In multivariable analysis, mechanical prostheses were less commonly implanted in older 
patients (odds ratio: 0.64 for every 10 years), and in patients with a history of cancer (0.72), 
but were more commonly implanted in mitral position (1.60). 
Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). 
Conclusions 
Patients with IE who receive a biologic valve replacement have significant differences in 
clinical characteristics compared to patients who receive a mechanical prosthesis. Biologic 
valve replacement is independently associated with a higher in-hospital and 1-year mortality, 
a result which is possibly related to patient characteristics rather than valve dysfunction. 
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INTRODUCTION 
Despite improvements in diagnosis, antibiotic treatment and surgery, infective 
endocarditis (IE) remains a serious disease, with 50% of patients requiring cardiac surgery 
during the acute phase of IE and a 20% in-hospital mortality.[1-3] Cardiac surgery for IE 
typically involves valve replacement with a mechanical or xenograft biologic prosthesis, 
although valve repair and homograft replacements may be used. The main advantage of 
mechanical prostheses is their longevity, but they require lifelong treatment with 
anticoagulants and the subsequent bleeding risks. Bioprostheses do not require long-term 
anticoagulation, but have a shorter durability, particularly in the mitral position. In its 2009 
guidelines on IE, the European Society of Cardiology did not favour any specific valve 
substitute but recommended a tailored approach for each individual patient and clinical 
situation.[4] The American College of Cardiology and the American Heart Association 
Valvular Disease Guidelines have stated that in general, a mechanical prosthesis is reasonable 
in patients under 65 years of age, while a bioprosthesis is favored in patients 65 years of age 
or older for both the aortic and the mitral positions, but do not provide specific 
recommendations for surgery in IE.[5] 
There are limited data to support the choice of either type of prosthesis in IE.[6] The 
characteristics of patients receiving biological or mechanical prosthesis and the association 
between type of valve prosthesis and outcome are not clearly defined. Thus, the objectives of 
this observational study were to describe the characteristics of patients according to the type 
of prosthesis and to examine the relationship between prosthesis type and 1-year mortality. 
 
METHODS 
International Collaboration on Endocarditis - Prospective Cohort Study 
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Data from the International Collaboration on Endocarditis - Prospective Cohort Study 
(ICE-PCS) were used for this study. Methods of this prospective, multicenter, international 
registry of IE have been previously reported.[7, 8] Between January 2000 and December 
2006, 5,668 patients from 64 centres in 28 countries were enrolled. The ICE-PCS database is 
maintained at the Duke Clinical Research Institute, which serves as the coordinating centre 
for ICE studies, with institutional review board approval from Duke University School of 
Medicine. All patients from sites meeting criteria for participation were included in ICE-PCS. 
Sites had to meet the following criteria: (1) minimum enrolment of 12 cases per year in a 
centre with access to cardiac surgery; (2) patient identification procedures in place to ensure 
consecutive enrolment and to minimize ascertainment bias; (3) high-quality data, including 
query resolution; and (4) institutional review board and/or ethics committee approval or 
waiver based on local standards. 
Patient Selection, Data Collection and Outcomes 
Patients were identified prospectively and consecutively enrolled in ICE-PCS if they 
met criteria for possible or definite IE based on modified Duke criteria.[9] Only the first 
episode of IE recorded for an individual patient was used in the analysis. Patients with 
definite IE who underwent valve surgery during the active phase of IE and who had biological 
or mechanical valve replacement were included. Exclusion criteria were: age <18 years old; 
intravenous drug user; patients treated with valve repair rather than replacement or who 
received a homograft or an autograft; patients receiving both a mechanical prosthesis and a 
bioprosthesis and patients whose 1-year survival data were missing. 
A standard case report form was used at all sites to collect data. The case report form 
included 275 variables and was developed by ICE according to standard definitions.[7] Data 
were collected during the index hospitalization and then entered at the coordinating centre or 
by site investigators using an Internet-based data entry system. Clinical characteristics 
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including demographics, comorbid conditions, pre-existing valvular conditions, details 
regarding the current episode of IE (including source of acquisition,[10, 11] microbiology and 
echocardiography findings, complications, management, and outcome) were collected. All 
sites were queried to obtain 1-year outcome data for survival, with use of national death 
indices, medical records, or patient contact, as available. 
Statistical analysis 
The outcomes of interest in this study were in-hospital and 1-year mortality. Data are 
presented as means (standard deviations) for continuous variables and as frequencies 
(percentages) for categorical variables. Simple comparisons were made with the Wilcoxon 
rank-sum test or the Chi-square test as appropriate. 
A generalized estimating equation method was used to determine factors that predicted 
implantation of a biological or a mechanical prosthesis. Variables found to have an 
association with the outcome of interest (p<0.05) on univariable analysis were considered for 
the final model in a backwards stepwise fashion. The final parameter estimates were 
converted to odds ratios (OR) with corresponding 95% confidence intervals (CI). 
A proportional hazards regression model was used to determine if prosthesis type was 
associated with 1-year mortality. Variables that differed significantly (p<0.05) between the 
two prosthesis groups in univariable analysis and clinically sound variables were considered 
for the final model. Survival times were censored at 1 year or date of last contact. Risk 
estimates are presented as hazard ratios and 95% CI. Survival curves were produced by 
plotting the estimated survival distribution obtained from the proportional hazards regression 
model, stratified by type of prosthesis. Influence of age was studied both per ten-year 
intervals and with a cutoff of 65 years according to the ACC-AHA valvular disease 
guidelines. 
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All tests were 2-sided, and statistical significance was determined at the 0.05 level. All 
statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). 
 
RESULTS 
There were 5,668 patients with definite and possible IE enrolled in the ICE-PCS. 
Based on pre-specified inclusion and exclusion criteria for this study, 1,467 patients, 
including 917 (63%) who received mechanical prostheses only and 550 (37%) who received 
bioprostheses only, were included in this study (Figure 1). 
The clinical characteristics of patients receiving biologic or mechanical prostheses are 
presented in Table 1. Compared to patients who received mechanical prostheses, those who 
received bioprostheses were older (61.6 SD 15.2 vs 53.6 SD 15.2 years; p<.0001), more often 
had a history of cancer (9% vs 6%; p=0.009) and moderate or severe renal disease (9% vs 4%; 
p<0.001). A higher proportion of bioprostheses were used in North and South America 
whereas in other regions of the world, mechanical prostheses were more frequently implanted. 
There were a higher proportion of health care-associated IE cases in the bioprosthesis group 
(26% vs 17%; p<.0001). For aortic valve replacement, bioprostheses were implanted more 
frequently than mechanical prostheses (61% vs 39%; p=0.06) whilst for mitral valve surgery, 
bioprostheses were less commonly implanted (34% vs 66%; p=0.002). Intracardiac abscesses 
were more frequent in the bioprosthesis group (30% vs 23%; p=0.0044). Both in-hospital and 
1-year death rates were higher in the bioprosthesis group, 20.6% vs 14.0% (p=0.0009) and 
25.3% vs 16.6% (p<.0001), respectively. For patients undergoing isolated aortic valve 
replacement, 1-year mortality after biologic versus mechanical valve replacement was 21.9% 
and 13.1% respectively; for patients undergoing isolated mitral valve replacement, 1-year 
mortality after biologic valve replacement was 26.3% compared to 20.3% for mechanical 
valve replacement. 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
8 
Only three variables independently predicted the implantation of a biological or a 
mechanical prosthesis. Compared to bioprostheses, mechanical prostheses were less 
commonly implanted in patients with increased age (OR: 0.64 for every 10 years; 95% CI: 
0.561 - 0.733), and in patients with a history of cancer (OR: 0.72; 95% CI: 0.526 - 0.979), but 
were more commonly utilized in mitral valve replacements (OR: 1.60; 95% CI: 1.289 - 
1.996). 
Multivariable analysis of 1-year mortality predictors is presented in Table 2. 
Bioprosthesis use was independently associated with 1-year mortality; the risk of death was 
increased by 30% (hazard ratio: 1.298 [1.011 - 1.665]; p = 0.0406). The hazard ratio was 
significantly higher in patients < 65 years of age (1.620 [1.123-2.339]) but not in patients ≥ 65 
years of age (0.845 [0.596-1.199]). Kaplan-Meier 1-year mortality estimates were 28.4% in 
the bioprosthesis group and 19.7% in the mechanical prosthesis group (p < 0.001) (Figure 2). 
After covariate adjustment, 1-year mortality estimates for biologic and mechanical prostheses 
were 24.7% and 20.5%, respectively (p = 0.0362). 
 
DISCUSSION 
In the present study, 1,467 patients received valve prostheses during the acute phase of 
IE with 37% receiving biologic valve replacement and 63% a mechanical prosthesis. Both in-
hospital and one-year mortality were higher in the bioprosthesis group. The higher mortality 
associated with bioprosthesis extended beyond the in-hospital acute phase of IE, and was 
independently associated with 1-year mortality in multivariable analysis. These results have 
relevance to current clinical practice, as biologic valve replacements were used in 
approximately 60% of valve replacement surgeries for IE in the United States from 2002 to 
2008.[12] 
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A few randomized trials have compared the outcome of biological versus mechanical 
prostheses, but none have included patients with IE. [13-15] In a Veterans’ Administration 
trial involving 575 patients undergoing single aortic or mitral valve replacement randomized 
to receive a biological or mechanical valve, the 15-year mortality after aortic valve 
replacement was higher with a bioprosthesis than mechanical prosthesis, but not after mitral 
valve replacement.[14] Bloomfield et al. randomized 533 patients to biological or mechanical 
prosthesis, and there was a non significant trend toward higher mortality after 12 years with 
the bioprosthesis.[13] However, in a meta-analysis of three trials, 5-year and 11-year 
mortality were not statistically different between the two types of prosthetic valves.[16] 
Other observational studies have compared the results of biologic or mechanical valve 
prosthesis for IE. In a previous study of 185 patients who received a valve prosthesis during 
the acute phase of IE, the 4-year mortality was higher in the bioprosthesis group.[17] In a 
small study of patients undergoing aortic valve replacement for aortic valve IE, 5-year 
mortality of patients who received biologic replacements (bioprostheses or homografts) was 
two-fold higher than for patients who received mechanical valve replacement, yet the 
increased mortality was evident only in patients less than 65 years of age.[18] Other studies 
have found no significant difference in mortality for biologic compared to mechanical valve 
replacement, but a higher rate of reoperation in younger patients who received biologic 
prosthesis.[19, 20] In a recent, retrospective study of patients on dialysis with IE who 
underwent valve surgery, no difference in longer term mortality was evident between type of 
valve prosthesis.[21] However, this cohort included patients treated with surgery beyond the 
acute phase of IE and the very high one-year mortality rate may have overshadowed any 
valve-related effect.[21] 
In the current study, the increased in-hospital and 1-year mortality associated with 
biologic valve replacement was evident only in patients younger than 65 years of age. This 
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early, increased mortality in younger patients was a surprising finding. Furthermore, the odds 
ratio associated with bioprosthetic valve type was modest relative to other variables related to 
1-year mortality. Although it is unlikely that biologic prostheses had valve degeneration or 
failure within 1-year follow up, data regarding post-operative echocardiographic assessment 
of the prostheses were not available. The selection of mechanical or biologic prosthetic valve 
in the setting of IE involves multiple considerations, including surgeon’s preference and 
experience, size and expected hemodynamics of the prosthetic valve, patient’s predicted 
longevity and valve durability, and risk of bleeding complications related to long-term 
anticoagulation. Although biologic valve replacement remained statistically associated with 
higher mortality after adjustment for certain chronic medical conditions, other variables which 
may have influenced type of valve prosthesis were not available for analysis in this study. 
Implantation of a biologic prosthesis in a younger patient may reflect other comorbid 
condition with reduced expected survival. On the other hand, among patients > 65 years of 
age, other medical conditions may be a greater determinant of mortality than the type of 
prosthesis implanted. The low C-statistic for the survival model may also indicate that 
baseline clinical characteristics associated with the acute IE episode are NOT strongly 
associated with 1 year survival in patients treated with surgery. Previous survival analyses 
have focused largely on in-hospital or shorter term mortality, but intermediate term mortality 
may be related to other factors not captured at baseline. 
This study has several other limitations. Since this is an observational study, the 
results are subject to selection bias such that unidentified variables may have influenced 
surgical decision-making regarding the type of prosthesis implanted. We could not ascertain 
whether in-hospital or 1-year mortality was due to a mechanical cardiac, infectious, or 
unrelated cause. Data regarding the use of anticoagulation after valve replacement and relapse 
of IE were not collected in this study, yet may have influenced outcome. 
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In conclusion, in a large, contemporary cohort of patients undergoing valve 
replacement surgery for active IE, bioprosthetic valve replacement was associated with higher 
in-hospital and 1-year mortality, particularly in patients younger than 65 years of age. Further 
studies are needed to determine factors related to type of prosthesis implanted in the setting of 
active IE and the valve-related outcome of these interventions. 
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Figure 1 - Disposition of subjects enrolled in the ICE-PCS cohort 
 
Figure 2 - One-year covariate-adjusted survival according to the type of valve prosthesis 
(Kaplan-Meier curves) 
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Fig. 1
Patients enrolled in ICE-PCS 
(n=5668) 
Patients analyzed 
(n=1467) 
Patients who received 
mechanical prostheses only 
(n=917) 
Patients who received 
bioprostheses only 
(n=550) 
Not definite IE (n=874) 
Intravenous drug users (n=465) 
Not operated patients (n=2100) 
Operated patients  
- Unknown type of surgery: 30 
- Surgery other than valvular: 272 
- Valve repair without prosthesis: 
130 
- Unknown type of prosthesis: 121 
- Patients who received a homograft 
or an autograft: 190 
- Patients who received a 
mechanical prosthesis and a 
bioprosthesis: 14 
(n=757) 
Missing 1-year survival data (n=5) 
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Fig. 2 
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Table 1 - Comparison of patients who received biological or mechanical prostheses 
 
Variable Level Overall Mechanical Bioprosthetic P-value 
  N % N % N %  
Total  1467 100 917 62.5 550 37.5  
Age < 65 years old  950 64.8 682 71.8 268 28.2 <.0001 
Age ≥ 65 years old  517 35.2 235 45.4 282 54.6  
Age (N=1466) Mean 1466 56.63 917 53.62 549 61.65 <.0001 
STD  15.66  15.16  15.21  
Gender (N=1465) Men 1053 71.88 665 72.68 388 70.55 0.3794 
Region (N=1467) North America 199 13.57 82 8.94 117 21.27  
South America 157 10.70 69 7.52 88 16.00  
 Australia/New 
Zealand/Africa 
227 15.47 156 17.01 71 12.91 <.0001 
 Europe 830 56.58 571 62.27 259 47.09  
 Asia/Mid East 54 3.68 39 4.25 15 2.73  
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Medical history 
History of cancer (N=1439)  106 7.37 54 5.98 52 9.70 0.0090 
Mild renal insufficiency (N=637)  51 8.01 25 6.41 26 10.53 0.0622 
Moderate or severe renal disease or 
haemodialysis dependent (N=1467) 
 88 12.61 39 9.49 49 17.07 0.0030 
Previous IE episode (N=1460)  123 8.42 65 7.13 58 10.58 0.0213 
Known native valve disease (N=1430)  472 33.01 312 35.14 160 29.52 0.0285 
Valve status at beginning of episode (N=1466) 
Aortic valve Native 1134 77.35 726 79.26 408 74.18  
Mechanical prosthesis 142 9.69 105 11.46 37 6.73 <.0001 
 Bioprosthesis 122 8.32 30 3.28 92 16.73  
 Other 66 4.64 53 6.00 13 2.36  
         
Mitral valve Native 1225 83.56 740 80.70 485 88.34  
Mechanical prosthesis 132 9.00 106 11.56 26 4.74 <.0001 
 Bioprosthesis 30 2.05 11 1.20 19 3.46  
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 Other 79 5.39 60 6.54 19 3.46  
         
Tricuspid valve Native 1394 95.09 862 94.10 532 96.73  
Mechanical prosthesis 4 0.27 2 0.22 2 0.36 0.0118 
 Bioprosthesis 4 0.27 1 0.11 3 0.55  
 Other 64 4.37 51 5.57 13 2.36  
         
Pulmonic valve Native 1405 95.84 870 94.98 535 97.27  
Mechanical prosthesis 2 0.14 0 0.00 2 0.36 0.0084 
 Other 59 4.02 46 5.02 13 2.36  
Present IE 
Health care-associated IE (N=1467)  295 20.11 154 16.79 141 25.64 <.0001 
Type of IE (N=1405) Native 1025 72.03 653 74.04 372 68.76 0.0938 
Prosthetic 380 26.70 218 24.72 162 29.94  
Location of vegetation (N=1371) No vegetation 101 7.32 54 6.24 47 9.14 0.0200 
Left heart only 1220 88.41 782 90.30 438 85.21  
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 Right heart only 22 1.59 8 0.92 14 2.72  
 Both left and right heart 28 2.03 16 1.85 12 2.33  
Fever > 38° C (N=1344)  1169 86.98 759 89.82 410 82.16 <.0001 
Worsening of old murmur or new 
murmur (N=1467) 
 870 59.30 587 64.01 283 51.45 <.0001 
Elevated C-reactive protein (N=1296)  983 75.85 644 77.87 339 72.28 0.0238 
Microorganisms (N=1467) 
Staphylococcus aureus  267 18.20 160 17.45 107 19.45 0.3350 
Coagulase negative staphylococci  177 12.07 100 10.91 77 14.00 0.0781 
Viridans group streptococci  273 18.61 188 20.50 85 15.45 0.0162 
Group D streptococci  122 8.32 81 8.83 41 7.45 0.3546 
Enterococcus  147 10.02 74 8.07 73 13.27 0.0013 
HACEK  17 1.16 9 0.98 8 1.45 0.4124 
Gram negative rods  37 2.52 21 2.29 16 2.91 0.4642 
Culture negative  143 9.75 98 10.69 45 8.18 0.1173 
Echocardiography 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
28 
New regurgitation (N=1457)  1127 78.26 728 81.16 399 73.48 0.0006 
Intracardiac vegetations (N=1461)  1277 88.43 810 90.00 467 85.85 0.0168 
Paravalvular complications (N=1459)  516 35.78 311 34.59 205 37.75 0.2253 
Surgery 
Aortic valve surgery (N=1465)  976 66.62 594 64.85 382 69.58 0.0629 
Mitral valve surgery (N=1464)  773 52.80 512 55.90 261 47.63 0.0022 
Complications 
Embolisation (N=1448)  324 22.38 217 24.06 107 19.60 0.0484 
Intracardiac abscess (N=1453)  377 25.95 212 23.40 165 30.16 0.0044 
Persistent positive blood cultures 
(N=1446) 
 91 6.29 46 5.09 45 8.29 0.0155 
In-hospital mortality (N=1466)  241 16.44 128 13.96 113 20.58 0.0009 
One-year mortality (N=1467)  291 19.84 152 16.58 139 25.27 <.0001 
IE: infective endocarditis; N=: number of patients for whom information is available; Health care-associated IE: inpatient, hospital acquired 
infection or health care related infection, non-hospital acquired (e.g. hemodialysis, outpatient chemotherapy, home intravenous antibiotics) 
No significant difference between the two groups for the following parameters: 
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· Medical history: chronic pulmonary disease, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, 
endocavitary device, diabetes mellitus, end organ damage, peptic ulcer disease, liver disease, connective tissue disease, hemiplegia, dementia, HIV 
infection 
· Complications: stroke, congestive heart failure, mycotic aneurysm 
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Table 2 - Parameters independently influencing 1-year mortality (multivariable 
analysis) 
 
Parameter Hazard ratio 95% confidence limits p-value 
Biological vs. mechanical prosthesis 1.298 1.011 - 1.665 0.0406 
Age in ten-year intervals 1.278 1.164 - 1.404 <.0001 
Type of IE: prosthetic valve 1.312 1.012 - 1.700 0.0404 
Elevated C-reactive protein 0.681 0.520 - 0.891 0.0050 
Diabetes mellitus 1.461 1.110 - 1.922 0.0069 
Haemodialysis-dependent 2.278 1.514 - 3.428 <.0001 
Viridans group streptococci 0.577 0.381 - 0.875 0.0096 
Healthcare-associated IE 1.430 1.082 - 1.889 0.0118 
Mitral valve vegetation 1.542 1.217 - 1.956 0.0003 
Congestive heart failure 1.681 1.322 - 2.139 <.0001 
Intracardiac abscess 1.697 1.318 - 2.184 <.0001 
Persistent positive blood cultures 1.575 1.080 - 2.298 0.0184 
Europe vs. other regions 1.869 1.411 - 2.476 <.0001 
C-index = 0.491 
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Highlights 
· In a large, contemporary cohort of 1,467 patients 
· undergoing biological (37% of patients) or mechanical (63% of patients) valve 
replacement surgery for definite active infective endocarditis, 
· bioprosthetic valve replacement was independently associated with higher in-hospital and 
1-year mortality, particularly in patients younger than 65 years of age. 
